These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22296687)

  • 21. Novel erythropoiesis-stimulating agents: a new era in anemia management.
    Macdougall IC
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of darbepoetin alfa on renal anemia in Japanese hemodialysis patients.
    Kusaba T; Ishida R; Nakayama M; Kato H; Uchiyama H; Sato K; Mori Y; Matsubara H; Kajita Y
    Arzneimittelforschung; 2009; 59(9):435-9. PubMed ID: 19856789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
    Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
    N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
    Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial.
    Johnson DW; Hawley CM; Rosser B; Beller E; Thompson C; Fassett RG; Ferrari P; MacDonald S; Pedagogos E; Cass A
    BMC Nephrol; 2008 Aug; 9():8. PubMed ID: 18671885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anemia in chronic kidney disease: causes, diagnosis, treatment.
    Nurko S
    Cleve Clin J Med; 2006 Mar; 73(3):289-97. PubMed ID: 16548452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
    Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
    Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes, anemia and CKD: Why TREAT?
    Singh AK
    Curr Diab Rep; 2010 Aug; 10(4):291-6. PubMed ID: 20544312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
    J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
    Milovanov IuS; Milovanova LIu
    Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
    Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.
    Doshi S; Chow A; Pérez Ruixo JJ
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):75S-90S. PubMed ID: 20881221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of darbepoetin therapy on platelet count and function in healthy cats and cats with surgically induced chronic kidney disease.
    De Lombaert MCM; Schmiedt CW; Lourenço BN; Tarigo JL; Hodges KM; Brainard BM
    Am J Vet Res; 2024 Aug; 85(8):. PubMed ID: 38889754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.